Dr. Arkin did his undergraduate work in biology and natural science at the University of Pennsylvania and he obtained his Medical Doctor degree at the New York University School of Medicine. He did his residency in pediatrics at Saint Christopher’s Hospital for Children and his fellowship in Pediatric Hematology/Oncology at the Morgan Stanley Children’s Hospital. Prior to joining Pfizer, Dr. Arkin was in the academic setting for 18 years in the field of Pediatric Hematology/Oncology. Steven Arkin, MD, is Executive Director of Pfizer’s Rare Disease and Research Unit. He joined Pfizer in 2005, by way of Wyeth, and has contributed to Pfizer programs in Hemophilia and other Rare Diseases and in Oncology

Steven Arkin has broad interest in a variant of activated coagulation factor X program in the clinic for treatment of intracerebral hemorrhage and the clinical lead for PF-06741086, an inhibitor of TFPI in the clinic for treatment of haemophilia, investigating hematopoiesis in bone marrow failure disorders, was principal investigator for numerous clinical research studies in haemophilia